Work

1736P An open label phase IIa study evaluating the preliminary efficacy of intratumoural tigilanol tiglate (TT) in advanced and/or metastatic soft tissue sarcoma (STS)

Year: 2024

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.1828

Authors: E.K. Bartlett, D. Li, S. Shemla, C.E. Ariyan, S. Dickinson, A. Crago, G. Li, N. Agaram, S.P. D'Angelo, R.G. Maki, S. Singer, W.D. Tap, C.M. Kelly

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Regeneron Pharmaceuticals, Astex Pharmaceuticals, Kowa Company, Foghorn Therapeutics, SkylineDx, Springworks Therapeutics, Servier, Ipsen, Qbiotics, EMD Serono, Daiichi Sankyo Europe

OpenAlex ID: W4402704818

FWCI:

Cites:

Cited by:

Related to: 10